Breaks Categories: News

TuesdayAug 18, 2026 9:30 am

PsychedelicNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Launches In-House CLIA-Certified Laboratory

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa, giving the company end-to-end control over processing of its multi-omics clinical tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), from sample receipt through result delivery. The facility received its federal Clinical Laboratory Improvement Amendments (“CLIA”) license following an inspection that found no deficiencies and has secured out-of-state licenses from California, Maryland, Rhode Island and Pennsylvania, with New York licensing in progress. Cardio Diagnostics said bringing processing in-house is expected to provide greater control over costs, quality and turnaround…

Continue Reading

WednesdayMay 27, 2026 10:35 am

PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company’s position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales. The commissioned report cites Optimi’s regulatory licenses, existing MDMA and psilocybin manufacturing capacity, expanding commercial activity in Australia and longer-term U.S. optionality, while outlining an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi’s asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development…

Continue Reading

TuesdayMay 05, 2026 9:50 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee Act in summer 2026, supported by stability data from multiple registration batches and a successful third-party manufacturing audit. To view the full press release, visit https://ibn.fm/yEXl3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone).…

Continue Reading

TuesdayApr 21, 2026 1:52 pm

PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) announced the launch of its Ibogaine Initiative to expand its Health Canada-licensed GMP manufacturing platform to include ibogaine production and supply, aligning with emerging U.S. regulatory momentum to accelerate psychedelic research and patient access. The move follows a recent U.S. executive order supporting clinical development and access pathways, including IND clearance for ibogaine trials, as Optimi positions itself to meet anticipated demand with regulated, pharmaceutical-grade supply while advancing its broader global strategy in MDMA and psilocybin therapies. To view the full press release, visit https://ibn.fm/CMDVt About Optimi Health Corp. Optimi Health…

Continue Reading

WednesdayApr 15, 2026 9:45 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown, and aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use, including a prototype in partnership with Zeta Surgical Inc. expected to be unveiled at the Clinical TMS…

Continue Reading

TuesdayApr 07, 2026 9:10 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the European Patent Office has issued a Rule 71(3) communication indicating its intent to grant a patent covering methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 (5-HT4) receptor agonists. The patent, exclusively licensed from Columbia University, is expected to strengthen the company’s intellectual property position across major European markets as Silo advances its pipeline targeting stress-related and central nervous system disorders. To view the full press release, visit https://ibn.fm/k9Vu8 About Silo Pharma,…

Continue Reading

MondayApr 06, 2026 9:20 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic Drugs indicating only minor formatting comments on the proposed label for its preservative-free ketamine product, with a final label submission expected this month and potential approval of its Abbreviated New Drug Application anticipated in Summer 2026 pending final review. The company noted the product could help expand U.S. ketamine supply amid reported shortages and aligns with federal efforts to re-shore critical drug manufacturing, while NRx also continues advancing a Fast Track-designated New Drug Application to evaluate intravenous ketamine for severe depression with suicidal ideation. To…

Continue Reading

MondayMar 16, 2026 9:10 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S. Food and Drug Administration support the agency’s willingness to review a New Drug Application for NRX-100, a preservative-free ketamine formulation, based on existing clinical trial data demonstrating substantial evidence of effectiveness without requiring additional clinical trials. The company said the FDA also confirmed openness to reviewing Real World Evidence as confirmatory data and indicated no additional nonclinical or bridging studies would be required, while NRx plans to pursue a primary indication for treating severe depression in patients who may experience suicidal ideation and continues to…

Continue Reading

ThursdayMar 12, 2026 9:20 am

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”) to address mental health conditions, announced the appointment of Jill Conwell as chief people officer, effective immediately. Conwell brings more than 20 years of leadership experience in the life sciences industry, with expertise in organizational strategy, talent development, corporate communications and investor relations. She has previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals and Shire Pharmaceuticals, where she helped build and scale organizations during periods of growth…

Continue Reading

MondayMar 09, 2026 9:10 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network of clinics and builds on a nationwide partnership with neurocare AG to bring non-invasive neuroplastic therapies to patients. Peer-reviewed publications cited by the company report an 87% clinical response rate in treatment-resistant depression using short-term treatment protocols, while pilot programs incorporating hyperbaric oxygen therapy have…

Continue Reading